Riskpilot← Back to searchSign inGet full accessCATAPULT LIFE SCIENCE AS
ASActiveOrg 917475644Martin Linges Vei 25, 1364 FornebuForskning og utviklingsarbeid innen bioteknologi · NACE 72110Est. 20160 employeescatapultlifescience.no
Revenue 2019
NOK 11,7M
+109% vs 2018
EBITDA margin
-16.0%
-10% vs 2018
Equity ratio
60.3%
Financial strength
Net profit 2019
NOK -4,5M
-79% vs 2018
| Revenue | NOK 11,7M | +109% |
| EBITDA | NOK -1,9M | -10% |
| Net profit | NOK -4,5M | -79% |
| Total assets | NOK 17,8M | -26% |
| Equity | NOK 10,7M | -30% |
| Employees | 0 | — |
Legal name
CATAPULT LIFE SCIENCE AS
Org number
917475644
Legal form
Aksjeselskap
NACE code
72110 · Forskning og utviklingsarbeid innen bioteknologi
Founded
3. august 2016
Share capital
NOK 74 840 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2019-12-31
Financial year
January – December
Signatory rights
Daglig leder og ett styremedlem i fellesskap
Company purpose
Å bidra til verdiskapning fra kompetansemiljøer innen livsvitenskap. Selskapet vil tilby tjenester og infrastruktur for å muliggjøre industrialisering, samt drive annen aktivitet som naturlig hører til dette.
Address
Martin Linges Vei 25, 1364 Fornebu
Email
info@catapultlifescience.no
Website
catapultlifescience.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2016 | 2017 | 2018 | 2019 |
|---|---|---|---|---|
| Revenue | 165 | 1 695 | 5 571 | 11 668 |
| Staff expenses | −0 | −1 638 | −3 488 | −7 853 |
| EBITDA | −349 | −2 441 | −1 696 | −1 866 |
| Depreciation & amort. | −6 | −290 | −765 | −2 509 |
| EBIT | −355 | −2 731 | −2 461 | −4 375 |
| Net financials | 0 | −22 | −59 | −143 |
| Profit before tax | −355 | −2 753 | −2 520 | −4 517 |
| Tax | −85 | 85 | −0 | −0 |
| Net profit | −270 | −2 838 | −2 520 | −4 517 |
| Item | 2016 | 2017 | 2018 | 2019 |
|---|---|---|---|---|
| Total assets | 589 | 5 179 | 23 865 | 17 772 |
| Equity | 245 | 1 979 | 15 229 | 10 712 |
| Long-term debt | 1 | 1 500 | 4 015 | 3 907 |
| Short-term debt | 343 | 1 700 | 4 621 | 3 153 |
| Total debt | 344 | 3 200 | 8 636 | 7 061 |
EBITDA margin
-16.0%
This company
15.8%
Market median
-201% vs market
20162019
Equity ratio
60.3%
This company
38.2%
Market median
+58% vs market
20162019
Return on equity
-42.2%
This company
18.4%
Market median
-329% vs market
20162019
Net profit margin
-38.7%
This company
8.1%
Market median
-578% vs market
20162019
Asset turnover
0.66×
This company
1.12×
Market median
-41% vs market
20162019
Debt / equity
0.66×
This company
0.62×
Market median
+6% vs market
20162019
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Brønnøysundsregistrene · Period 2016-01-01 – 2016-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
KM Chief Executive Officer | Chief Executive Officer | 2020 |
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
| Board of Directors | 2020 | |
| Board of Directors | 2020 | |
| Board of Directors | 2020 | |
| Chairman | 2020 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of CATAPULT LIFE SCIENCE AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Kristin Merete Schoultz | Chief Executive Officer | 0 companies |
| Naja Dannow | Board of Directors | 0 companies |
| Anders Stokvold | Board of Directors | 0 companies |
| Kjeld-Håkon Langeland Nilsen | Board of Directors | 0 companies |
| Trond Høgh Johansen | Chairman | 0 companies |